The ADDF Presents the 21st International Conference on Alzheimer’s Drug Discovery

The Alzheimer’s Drug Discovery Foundation (ADDF) will host its 21st International Conference on Alzheimer’s Drug Discovery, bringing together internationally-recognized researchers from both academia and industry to discuss recent discoveries and drug developments in Alzheimer’s disease and related dementias. The conference will take place virtually on October 5 and 6.

The program is broken up into five sessions consisting of exciting keynotes and scientific lectures, as well as live Q&As discussing novel approaches for neuroinflammation, metabolic and mitochondrial approaches for Alzheimer’s disease, emerging areas in drug development for neurodegeneration, novel biomarkers in Alzheimer’s disease, and neuroprotection, among other research focus areas.

The conference will also include a start-up forum and virtual poster presentations, with opportunities to speak with the presenters. “We are excited to hear the latest updates from our funded investigators, whose diverse approaches exemplify the ADDF’s commitment to a robust and varied portfolio, targeting multiple pathways to give us the best chance of finding treatments for this complex disease,” said Howard Fillit MD, Founding Executive Director and Chief Science Officer of the ADDF.

Highlights of the ADDF’s 21st International Conference on Alzheimer’s Drug Discovery will include:

• Two keynote talks: Gene Therapy for Neurodegeneration, presented by Ron Crystal, MD of Cornell University, and The Current State of Blood Biomarkers in Alzheimer’s Disease, presented by Henrik Zetterberg, MD, PhD of the University of Gothenburg
• Clinical Trial Results: Glutamate Modulator Riluzole in Patients with Mild Alzheimer’s Disease, presented by Ana Pereira, MD of the Icahn School of Medicine
• Digital Biomarkers in Alzheimer’s Disease, presented by Lampros Kourtis, PhD of Circadic
• Phase 1b Study in AD Patients with Neuroinflammation, presented by CJ Barnum, PhD of INmune Bio

To view the full program for the 21st International Conference on Alzheimer’s Drug Discovery or to register for free, visit our conference page.